Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
SEC filing
Latest
4 stories
Yesterday
Tuesday, August 11
CRISPR Therapeutics registers Phase 1/2 trial of CTX340 for treatment-resistant hypertension
Monday, August 10
Monday, August 3
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial starts
FDA cleared CASGEVY for children as young as 2, and the company began Phase 1 trials for CTX340 and CTX460 while cash stood at $2,364.4 million.
SEC filing